2149. Briggs AH, Goldstein DA, Kirwin E, Meacock R, Pandya A, Vanness DJ, et al. Estimating （quality-adjusted） life-year losses associated with deaths: With application to COVID-19. Health Economics. 2021; 30（3）: 699-707. https://onlinelibrary.wiley.com/doi/abs/10.1002/hec.4208.50. Garratt A, Hansen T, Augestad L, Rand K, Stavem K. Norwegian population norms for the EQ-5D-5L: results from a general population survey. Quality of Life Research. 2022 02; 31: 1-10.51. Statistics Norway. Døde, etter kjønn og 1- ˚arige alders-grupper 1986-2023. Oslo, Norway; 2024. Last accessed on 2024-09-03. https://data.ssb.no/api/v0/no/table/10325.52. Eurostat. Labour market slack by sex and age - quarterly data; 2024. Last accessed on 2024-06-17. https://ec.europa.eu/eurostat/databrowser/view/lfsi_sla_q/default/table?lang=en&category=labour.employ.lfsi.une.3953. Dingel JI, Neiman B. How many jobs can be done at home? Journal of Public Eco-nomics. 2020; 189: 104235. https://www.sciencedirect.com/science/article/pii/S0047272720300992.54. John H, Dragos, A, Elisa S. Recovery from COVID-19: The changing structure of employment in the EU; 2022. Euro-found. https://www.eurofound.europa.eu/en/publications/2022/recovery-covid-19-changing-structure-employment-eu#:~:text=andlabourmarkets-, RecoveryfromCOVID-19: Thechangingstructure,ofemploymentintheEU&text=Europeanlabourmarketshaverecovered,almostatpre-crisislevels.55. Eurostat. Gross domestic product at market prices; 2024. Last accessed on 2024-06-06. https://ec.europa.eu/eurostat/databrowser/view/tec00001/default/table.56. Commission E. Report on the European instrument for Temporary Support to mitigate Unemployment Risks in an Emergency （SURE） following the COVID-19 out-break pursuant to Article 14 of Council Regulation （EU） 2020/672 SURE after its sunset: final bi-annual report. Brussels; 2023. COM （2023） 291 final.57. FEDS Notes. Why is the U.S. GDP recovering faster than other advanced economies?; 2024. Last accessed on 2024-08-28. https://www.federalreserve.gov/econres/notes/feds-notes/why-is-the-u-s-gdp-recovering-faster-than-other-advanced-economies-20240517.html.58. Adascalitei D, vacas soriano C, Staffa E, Hurley J. Tele-work and teleworkability during COVID: An analysis using LFS data. Eurofound working paper. 2022 07.59. Chernozhukov V, Kasahara H, Schrimpf P. Causal impact of masks, policies, behavior on early covid-19 pandemic in the U.S. Journal of Econometrics. 2021; 220（1）: 23-62. Pandemic Econometrics. https://www.sciencedirect.com/science/article/pii/S0304407620303468.60. Li Y, Liang M, Gao L, Ayaz Ahmed M, Uy JP, Cheng C, et al. Face masks to prevent transmission of COVID-19: A systematic review and meta-analysis. American Journal of Infection Control. 2021 Jul; 49（7）: 900-6. https://doi.org/10.1016/j.ajic.2020.12.007.61. Jefferson T, Dooley L, Ferroni E, Al-Ansary L, van Driel M, Bawazeer G, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews.2023; （1）. https://doi.org//10.1002/14651858.CD006207.pub6.63. Yang J, Vaghela S, Yarnoff B, et al. Estimated global public health and economic impact of COVID-19 vac-cines in the pre-omicron era using real-world empirical data. Expert Rev Vaccines. 2023; 22（1）: 54-65. doi:10.1080/14760584.2023.215781764. Matza LS, Stewart KD, Naegeli AN, et al. Qualitative interviews to evaluate content validity of the ACTIV-2 COVID-19 Symptom Diary （ACSD）. J Patient Rep Outcomes. 2023; 7（1）: 8. Published 2023 Jan 31. doi:10.1186/s41687-022-00535-x65. Mendes D, Chapman R, Aruffo E, et al. Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance. Expert Rev Vaccines. 2023; 22（1）: 90-103. doi:10.1080/14760584.2023.215881666. Keeley TJH, Satram S, Ghafoori P, et al. Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus （FLU-PRO Plus©） instrument in patients with COVID-19 ［published online ahead of print, 2023 Jan 27］. Qual Life Res. 2023 ;1 -13 . doi:10.1007/s11136-022-03336-367. Di Fusco M, Marczell K, Deger KA, et al. Public health impact of the Pfizer-BioNTech COVID-19 vaccine （BNT162b2） in the first year of rollout in the United States. J Med Econ. 2022; 25（1）: 605-617. doi:10.1080/13696998.2022.207142768. Mendes D, Chapman R, Gal P, et al. Public health impact of booster vaccination against COVID-19 in the UK dur-ing Delta variant dominance in autumn 2021. J Med Econ. 2022; 25（1）: 1039-1050. doi:10.1080/13696998.2022.211193569. Tervonen T, Jimenez-Moreno AC, Krucien N, Gelhorn H, Marsh K, Heidenreich S. Willingness to Wait for a Vac-cine Against COVID-19: Results of a Preference Survey. Patient. 2021; 14（3）: 373-377. doi:10.1007/s40271-020-00483-y70. Angelis A, Baltussen R, Tervonen T. The Need for Novel Approaches in Assessing the Value of COVID-19 Vac-cines. Am J Public Health. 2021; 111（2）: 205-208. doi:10.2105/AJPH.2020.306066*North America group62. Pierre V, Draicab F, Di Fusco M, Yang J, Nunez-Gonzalez S, Kamara J, Lopez S, Moran MM, Nguyen J, Alvarez P, Cha-Silva A, Gavaghan N, Yehoshua A, Stapleton N, Burnett H. J MED ECON 2023 Doi 10.1080/13696998.2023.2281882日立感染症関連研究支援基金 研究成果報告書
元のページ ../index.html#23